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Abstract
Objective: Nerve injuries resulting in prolonged periods of denervation result in
poor recovery of motor function. We have previously shown that embryonic stem
cell-derived motoneurons transplanted at the time of transection into a peripheral
nerve can functionally reinnervate muscle. For clinical relevance, we now focused
on delaying transplantation to assess reinnervation after prolonged denervation.
Methods: Embryonic stem cell-derived motoneurons were transplanted into the
distal segments of transected tibial nerves in adult mice after prolonged denerva-
tion of 1–8 weeks. Twitch and tetanic forces were measured ex vivo 3 months
posttransplantation. Tissue was harvested from the transplants for culture and
immunohistochemical analysis. Results: In this delayed reinnervation model, ter-
atocarcinomas developed in about one half of transplants. A residual multipotent
cell population (~ 6% of cells) was found despite neural differentiation. Exposure
to the alkylating drug mitomycin C eliminated this multipotent population
in vitro while preserving motoneurons. Treating neural differentiated stem cells
prior to delayed transplantation prevented tumor formation and resulted in
twitch and tetanic forces similar to those in animals transplanted acutely after
denervation. Interpretation: Despite a neural differentiation protocol, embryonic
stem cell-derived motoneurons still carry a risk of tumorigenicity. Pretreating
with an antimitotic agent leads to survival and functional muscle reinnervation if
performed within 4 weeks of denervation in the mouse.
Introduction
Pathologies characterized by motoneuron (MN) death or
axonal injury lead to muscle denervation and loss of
motor function resulting in impairment in quality of life
and longevity.1,2 Amyotrophic lateral sclerosis, spinal cord
injuries, nerve root avulsion, and plexus injuries result in
motor dysfunction, either due to MN demise3 or irre-
versible denervation.
Restoring function to paralyzed muscles can be achieved
with functional electrical stimulation provided the targeted
muscle retains some innervation.4 This strategy is far less
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effective if the targeted muscles lack innervation because
large currents are required to directly activate denervated
myofibers.5 Consequently, we and others have explored the
possibility of combining cell replacement therapy with
electrical stimulation to restore function to permanently
denervated muscles. Collectively, these studies have shown
that MNs derived from embryonic ventral spinal cord
cells,6 embryonic stem (ES) cells,7 or induced pluripotent
stem (iPS) cells8 can functionally innervate denervated
muscle fibers when transplanted into the peripheral nerve
near the target muscle.6–10 Although the innervating MNs
do not fully restore predenervated contractile force, the
level of force achieved when electrically stimulated is likely
sufficient to provide meaningful function. For example,
transplanted embryonic stem cell-derived motoneurons
(ESCMNs) innervate denervated fibers and generate ~40%
of the original contractile force when electrically stimu-
lated, provided the cells were grafted immediately after
muscle denervation.7 These studies demonstrate proof of
principle that cells transplanted into peripheral nerves can
be stimulated to control muscle contraction.
In clinical practice, however, surgical interventions to
improve denervation injuries are generally delayed to
allow for spontaneous recovery.11 The same practice
would apply if transplantation procedures were to be
implemented. This delay could impact transplantation
outcomes because the local environment postdenervation
changes as time progresses.12 For translational purposes,
it is therefore necessary to demonstrate that MNs can be
transplanted after prolonged denervation and still provide
functional innervation.
ES and iPS cells are alluring for cell replacement thera-
pies: they can be expanded into large numbers and be
directed to differentiate into specific neuronal types,
including functional MNs.13,14 However, ES and iPS cells
have been associated with the development of untoward
outcomes following transplantation, such as the develop-
ment of tumors.15,16 Tumorigenesis likely results because
the differentiation protocols lead only to enrichment of a
specific cell type and do not completely eliminate
pluripotent progenitor cells.17 Consequently, strategies
must be developed to eliminate the risk of tumorigenesis
before these cell types can be used clinically.
Here, we sought to establish a safe and effective means
to transplant ESCMNs into peripheral nerves following
prolonged denervation. We initially found that transplant-
ing ESCMNs following a delay resulted in nearly half of
the transplanted animals developing teratocarcinomas.
We demonstrate that pretreating the ESCMNs with the
alkylating agent mitomycin C eliminated residual pluripo-
tent cells following differentiation while sparing terminally
differentiated MNs. Mitomycin C treatment prevented
tumor formation and led to functional reinnervation after
prolonged injury similar to that seen following transplan-
tation after acute denervation.
Materials and Methods
ESCMN cell preparation
HB9, a homeobox gene, is expressed in embryonic MNs
early after differentiation from neuronal progenitors.18,19
An Hb9-eGFP ES cell line on a pure C57Bl6 background,
denoted as HBGB6, was generously provided by Dr. Craig
Cox (Jackson, ME) and was used to generate MNs.
ESCMNs were generated by treating free-floating clusters
of ES cells known as embryonic bodies (EB) with retinoic
acid (1 lmol/L; Sigma Aldrich, Oakville, ON, Canada) and
smoothened agonist (500 nmol/L; Enzo Life Sciences,
Farmingdale, NY, USA) as described previously.7,13,14 Dif-
ferentiated EBs were enzymatically dissociated in Tryple
express (ThermoFisher Scientific, Ottawa, ON, Canada)
with 0.01% (w/v) DNaseI (Sigma-Aldrich). The obtained
single cell suspension was resuspended in DFK10.14 For
in vitro experiments, 105 dissociated cells were plated onto
growth factor reduced matrigel (BD Biosciences, Rockville,
MD, USA)-coated glass coverslips (ThermoFisher Scienti-
fic). In vitro cells were maintained in DFK10 supplemented
with 10 ng/mL GDNF (Millipore, Etobicoke, ON, Canada)
and 10 ng/mL CNTF (ThermoFisher Scientific). Media was
changed every other day.
Surgery
All procedures were performed in accordance with protocols
approved by the Dalhousie University Animal Care Com-
mittee, and conformed to the standards of the Canadian
Council of Animal Care. Transplantation was performed as
described previously.7 In summary, under deep anesthesia,
the tibial nerve of 5-week-old C57Bl6 mice (Charles River)
was transected at midthigh level. Both nerve ends were
ligated and the proximal end was buried into adjacent mus-
cle to prevent spontaneous reinnervation. ESCMN trans-
plantation was done either immediately after transection or
after a delay period of 1, 2, 4, or 8 weeks posttransection.
Ten thousand differentiated cells in 0.1 lL containing
0.01%DNaseI, 20 lg/mL CNTF, and 10 lg/mL GDNF were
transplanted using a glass micropipette into the transected
distal tibial nerve, which was subsequently proximally
ligated. All distal branches except the medial gastrocnemius
(MG) nerve branch were transected.
In vitro electrophysiology
The MG muscle together with the tibial nerve was har-
vested 3 months after transplantation as described
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previously.7 Forces were measured with a force transducer
(FT03, Grass Technologies, West Warwick, RI, USA) con-
nected to an AC/DC strain gage amplifier (P122, Grass
Technologies). A glass suction electrode was used to pro-
vide stimuli to the MG nerve via a square pulse stimula-
tor (S88, Grass Technologies) isolated from ground by a
constant current stimulus isolator (PSIU6, Grass Tech-
nologies). EMG recordings were obtained with a poly-
ethylene suction electrode (PE-190, Clay Adams, Sparks,
MD, USA) applied over the muscle midbelly. EMG signal
was amplified with a differential amplifier (EX4-400,
Dagan Corporation, Minneapolis, MN, USA) and band-
pass filtered between 0.3 Hz and 3 kHz. Signals were
recorded via a Digidata 1320A, using Axoscope 9.2 soft-
ware (Molecular Devices, Sunnyvale CA, USA). Supra-
maximal stimulation was performed at 1.59 the stimulus
necessary to provide maximal twitch force (usually
100 lA, 0.2 msec). Tetanic stimulation was performed at
50 Hz for 500 msec. Motor unit (MU) sizes were esti-
mated by force increments7,20 obtained by stepwise
increases of the stimulus. Motor unit number estimation
was estimated by dividing the whole muscle twitch force
by the averaged MU force obtained after seven force
increments. The susceptibility of the muscle to fatigue
was quantified by calculating the ratio between the force
generated after a 2-min tetanic stimulation by the force at
the onset of the stimulation as described previously.7
Tumor tissue harvesting and culture
Upon palpable tumor formation from ESCMN trans-
plantation, mice were anesthetized and the tumor was
dissected under sterile conditions in terminal
experiments. One half of the tumor was fixed and pro-
cessed for paraffin embedding and thin slice hematoxylin
and eosin histochemistry. The other half was kept for
cell culture. Tissue was sharply fragmented in a slurry in
Ca2+/Mg2+-free HBSS, washed multiple times before
enzymatically digested in trypsin-EDTA (1–0.25%,
Sigma-Aldrich) for 30 min at 37°C with constant agita-
tion. The cell suspension was spun and washed with
DMEM supplemented with 10% fetal calf serum (Gibco)
followed by trituration, washing, and filtration over a
40-lm cell filter (Millipore). In order to generate cell
colonies, 106 cells were plated onto a feeding layer of
mitomycin C-treated primary mouse embryonic fibrob-
lasts (Stem Cell Technologies, Vancouver, BC, Canada)
in ES media as previously described.13,14 Media was sup-
plemented with 29 penicillin–streptomycin (Gibco) and
2.5 lg/mL amphotericin B (Sigma-Aldrich). Media was
changed daily for the first week. Initial colonies were
passaged on the fifth day in culture and every second
day thereafter. Passaging of colonies was performed as
described previously for mouse ES cultures.
Immunohistochemistry
Cells were fixed in 1% paraformaldehyde in PBS for
20 min, followed by three washes in PBS, then perforated
and blocked for 20 min in PBS-0.3% triton-X (v/v,
Sigma-Aldrich) supplemented with 10% donkey serum
before incubation with primary antibodies. Cells were
washed three times in PBS between each step. Nuclei were
stained with Hoechst 33342 (Sigma-Aldrich) 0.1 lg/mL
for 20 min in PBS. Primary and secondary antibodies are
described in Table 1.
Table 1. Antibodies.
Primary antibodies
Antiserum Host Subtypes Dilutions Incubation Sources Cat. Number
GFP Rabbit IgG 1:1000 1 h Millipore AB3080
GFP Sheep IgG 1:1000 O/N Novus Biologicals NB100-62622
TUJ1 Mouse IgG2a 1:1000 1 h Covance MMS-435P
SSEA-11 Mouse IgM 1:10001 1 or 72 h Cell Signaling 4744
Sox2 Mouse IgG1 1:100 72 h Cell Signaling 4900
Oct4A Rabbit IgG 1:100 72 h Cell Signaling 2840
Secondary antibodies
Antiserum Host Conjugates Dilutions Incubation Sources Cat. Number
Anti-rabbit IgG Donkey AF488 1:500 1 h Thermo Fisher Scientific A-21206
Anti-sheep IgG Donkey AF488 1:500 O/N Thermo Fisher Scientific A-11015
Anti-mouse IgG Donkey AF546 1:500 1 h or O/N Thermo Fisher Scientific A10036
Anti-mouse IgM Goat AF546 1:5001 1 h or O/N Thermo Fisher Scientific A-21045
Anti-rabbit IgG Donkey AF647 1:500 O/N Thermo Fisher Scientific A-31573
1Best staining results obtained without cell perforation, used at 1:100 for 20 min for FACS experiments, 72 h incubation performed when
combined with Sox2 and Oct4A.
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Mitomycin C treatment
To quantify the effect of mitomycin C on ESCMNs,
differentiated EBs were incubated with increasing con-
centrations of mitomycin C (from 0.01 lg/mL to
10 lg/mL, Sigma-Aldrich) for 2 h followed by three
washes in HBSS, dissociation as described above, and
plating with neuroprogenitor cells (NPC) in an equal
ratio on matrigel-coated coverslips.21 The presence of
astrocytes from NPC was essential to maintain adhesion
of ESCMNs to the coverslips for more than 3 days.22
Coverslips were fixed after 3, 5, or 7 days in vitro.
SSEA-1 immunofluorescence was used to identify undif-
ferentiated cell colonies; ESCMN GFP signal was
enhanced by immunofluorescence. ESCMNs and undif-
ferentiated cell colonies were counted by selecting five
random fields per coverslip with a 109 objective (area
of 2.95 mm2).
To quantify apoptotic cells by FACS after mitomycin C
treatment, differentiated EBs were treated with 1 lg/mL
mitomycin C for 2 h, washed, and incubated for 12 h in
DFK10 with 10 lg/mL GDNF and CNTF prior to dissoci-
ation. Annexin-V labeling (Thermo Fisher Scientific) was
performed as per the manufacturer’s protocol with minor
modifications. Dissociated cells were first immunolabeled
with primary antibody against SSEA-1 (Table 1) for 1 h
at 4°C in cold annexin-binding buffer with constant agi-
tation. After washing, annexin-V labeling was initiated.
Secondary antibody staining for SSEA-1 was performed
during the annexin-V conjugate incubation step. Cells
were kept on ice until analyzed by FACS (BD FACS
AriaIII) for the expression of eGFP, SSEA-1, and
annexin-V.
Mitomycin C treatment for ESCMN transplantation
was performed in vitro with 1 lg/mL exposure for 2 h
prior to EB dissociation. EBs were washed three
times with HBSS and dissociated as per the above pro-
tocols.
Imaging
Color images were obtained on an Axioplan II (Zeiss
Microimaging, Thornwood, NY, USA) microscope
equipped with a color Axiocam HRC camera (Zeiss).
Confocal images were obtained on a Zeiss LSM710 confo-
cal microscope running Zen software (Zeiss). Images were
transferred to ImageJ (NIH) for analysis.
Statistical analysis
Results are presented as means  standard deviations.
One-way analysis of variance (ANOVA) was used to
compare electrophysiological data between experimental
and control groups and between immediate and delayed
experimental groups. Kruskal–Wallis tests and Dunn’s
multiple comparisons were applied to identify significant
differences. Two-way ANOVA with Bonferroni multiple
comparisons was used for mitomycin C experiments.
Freeman–Halton extension of the Fisher’s exact probabil-
ity test was used for innervation success ratios. Statistics
were calculated using GraphPad Prism version 6.00 for
Mac (GraphPad Software, La Jolla, CA, www.graphpad.-
com).
Results
Teratocarcinoma formation following
transplantation
To ask whether delayed MN transplantation studies could
be successful, we used a mouse stem cell line derived
from a pure C57Bl6 background (denoted as HBGB6), in
which ESCMNs express GFP. Following delayed trans-
plantation, however, there was limited evidence of rein-
nervation: 1 week after immediate transplantation, GFP+
cells were seen in only two of the six mice. In a series of
17 transplants, only 5 (30%) were able to generate force
at 3 months (3/10 immediate and 2/7 1 week delayed
transplants). Four of the remaining 12 transplanted ani-
mals had no sign of the graft, while eight generated
tumors by 1 month (Fig. 1A–C). The tumors were con-
sistent with teratomas, with the presence of all three
embryonic lineages on histology: ectoderm (neurons,
Fig. 1D), mesoderm (cartilage, Fig. 1E), and endoderm
(gastrointestinal mucosa, Fig. 1F). Malignant histological
features were also identified: mitotic figures (Fig. 1G),
nuclear atypia and hypercellularity (Fig. 1H), and necro-
sis (Fig. 1I), indicating the tumors were teratocarcino-
mas.
To confirm the diagnosis of teratocarcinoma, we next
asked whether pluripotent cells remained within the
tumors.23 To do so, we isolated and dissociated the
tumors, and cultured them on primary mouse embry-
onic fibroblasts. We found colonies typical of stem cells
that could be renewed for over 1 month when passaged
every second day. These colonies were positive for the
pluripotent markers SSEA-1, Oct-4A, and Sox2
(Fig. 2A). Furthermore, these tumor-derived colonies
could be differentiated into GFP+ MNs by treatment
with retinoic acid and smoothened agonist as previously
described for mouse ES cells.13,14 GFP expression was
observed as early as the third passage, 2 days in vitro
(Fig. 2B), and was maintained even following 15
passages (1 month). In addition to GFP+ cells,
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bIII-tubulin+/GFP cells were also present, demonstrat-
ing that these tumor-derived pluripotent cells, like ES
cells,13,14 differentiated into more than one postmitotic
neuronal type (Fig. 2C). Taken together, these results
indicate that the observed tumors contained pluripotent
cells that could be differentiated into a number of neu-
ron types, including MNs. Furthermore, this shows that
the development of malignant teratocarcinomas is a sub-
stantial risk in mice when differentiated stem cells are
used for transplantation.
Figure 1. Embryonic stem cell-derived motoneurons (ESCMN) transplants led to formation of teratocarcinomas. (A–C) Macroscopic appearance of
tumor. This first tumor appeared rapidly and unexpectedly. Once aware of this issue, we ensured that no further tumors grew larger than a palpable
size of 1 cm. (D–I) Microscopic images of tumors originating from transplanted ESCMNs. All three germ lineages were present in tumors consistent
with the formation of a teratomatous tumors: epidermal lineage (neuron: arrow, D), mesodermal lineage (cartilage: E), and endodermal lineage
(ciliated glandular epithelium with goblet cells: F). Characteristics of a malignant teratoma (teratocarcinoma): high mitotic rate (arrows pointing at
mitotic figures; G, enlarged view G’), hypercellularity with nuclear atypia (H, enlarged view H’), and intratumoral necrosis (I, enlarged view I’).
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Pluripotent cells remain even after
differentiation of stem cells
We next examined the extent to which pluripotent cells
remained following differentiation of ES cells into MNs,
prior to transplantation. We found that following differ-
entiation, ESCMN cultures contained cells expressing the
pluripotent markers SSEA-1, Oct4A, and Sox2 (Fig. 3A).
By combining live cell immunolabeling with FACS analy-
sis we found that 6  2% (n = 3) of the cells expressed
SSEA-1 after differentiation protocol. Once plated, all
wells (n > 12) with differentiated ESCMNs formed SSEA-
1-expressing colonies as early as 3 days in vitro. These
data indicate that residual pluripotent cells persisted
within differentiated ESCMN cultures, and suggest that
these pluripotent cells were the substrate for the malig-
nancies.
Treatment with mitomycin C eliminates
pluripotent cells
Our next strategy was based on the reasoning that since
neurons are mitotically inactive, pluripotent cells could be
selectively eliminated while neurons were preserved by an
alkylating agent. We therefore treated differentiated EBs
with mitomycin C for 2 h and immunolabeled the cells
with SSEA-1 and the apoptotic marker annexin-V. SSEA-
1+ cells were isolated using FACS and then further ana-
lyzed for their expressing of annexin-V and GFP. This
showed that the proportion of SSEA-1+ cells expressing
annexin-V was twice as high in the mitomycin C-treated
group (Fig. 3B, mitomycin C lower right quadrant) com-
pared to control (Fig. 3B, control lower right quadrant).
To test whether this increase in annexin-V was associated
with a reduction in the number of pluripotent cells, we
treated the differentiated dissociated EBs with mitomycin
C, and then cultured them for 1 week. This eliminated
pluripotent cells, as demonstrated by the absence of
SSEA-1+ cells in the mitomycin C-treated cultures
(Fig. 3C). Concentrations of at least 1 lg/mL of mito-
mycin C were required to effectively eliminate SSEA-1+
cells from the cultures (Fig. 3D). Thus, mitomycin C was
found to be effective at eliminating undifferentiated
pluripotent cells from EBs.
We next asked whether mitomycin C was toxic to
MNs. Three days after differentiation and dissociation,
there were fewer ESCMNs after treatment with mitomycin
C compared to untreated controls. However, by 5 days
in vitro, there was no difference in ESCMN numbers
(Fig. 4E) with controls. At all time points, however, sur-
vival of MNs was significantly decreased when EBs were
treated with ≥5 lg/mL mitomycin C. Of note, mitomycin
C treatment also ablated glial progenitors such that no
cells were labeled with glial fibrillary acidic protein
(GFAP) at 1 week in vitro, a time when strong GFAP
staining is normally seen in cultures of untreated differen-
tiated ES cell lines. Thus, mitomycin C treatment of 1–
2 lg/mL was effective at eliminating pluripotent cells
while preserving differentiated MNs.
Mitomycin C prevents the formation of
teratocarcinomas leading to successful
reinnervation
Given that incubation with mitomycin C led to elimina-
tion of pluripotent cells, we next tested whether mito-
mycin C-treated ESCMNs formed tumors after
transplantation. ESCMNs treated with mitomycin C did
not engraft after immediate transplantation (n = 6).
However, when mitomycin C-treated ESCMNs were
transplanted 1–4 weeks after tibial nerve transection, none
(0/20) of the animals developed tumors, indicating that
mitomycin C was effective at preventing the formation of
teratocarcinomas.
We next determined whether the treated ESCMNs sur-
vived and innervated muscle when transplanted into the
peripheral nerve of mice. Treating the cells prior to trans-
plantation with mitomycin C resulted in successful inner-
vation after delayed transplantation: six of the eight
animals following 1 week delay; three of the six animals
after 2 weeks delay; and two of the six animals after
4 weeks delay (Table 2). None of the transplants per-
formed after 8 weeks delay resulted in successful MG
innervation. Furthermore, twitch and tetanic forces after
3 months were similar to those found after immediate
transplantation of nonmitomycin-treated ESCMNs
(Fig. 4A–D; as immediate transplantation after mitomycin
C did not engraft, forces from immediate transplants in
Fig. 4 are from nonmitomycin C-treated ESCMNs in ani-
mals that did not generate tumors). It should be noted,
however, that a single pulse of electrical stimulation
resulted in doublet or triplet EMG depolarizations
Figure 2. Pluripotent cells isolated from teratocarcinomas generated from transplanted ESCMNs can be differentiated into motoneuron (MNs)
in vitro. (A) Pluripotent cells isolated from dissociated teratocarcinoma tissue formed colonies expressing the stem cell markers SSEA-1, Sox2, and
Oct4A. Hoechst staining was used to visualize individual nuclei. (B) Following treatment with retinoic acid and a smoothen agonist, embryonic
bodies (EBs) generated from teratocarcinoma-derived cells contain GFP+ MNs after 2 and 7 days in vitro. (C) Dissociated and plated EBs that were
treated for 5 days in vitro with retinoic acid and a smoothened agonist, contained GFP+ MNs and bIII-tubulin+ cells that were GFP after 2 days
in vitro. ESCMNs, embryonic stem cell-derived motoneurons.
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(Fig. 4A’). These multiple depolarizations likely accounted
for larger twitch amplitude (compared to smaller tetanic
amplitude) in the example shown following a 4-week
delay (Fig. 4A, C), and the longer than normal half-
relaxation times induced by the single pulse contractions
(Table 3). Interestingly, all other contractile
Figure 3. Residual pluripotent cells postembryonic stem cell-derived motoneurons (ESCMN) differentiation from HBGB6 are sensitive to
mitomycin C. (A) Dissociated differentiated embryonic bodies (EBs) grown for 5 days in vitro on matrigel demonstrate the formation of colonies
expressing pluripotent markers (SSEA-1, Oct4A, Sox2) in the absence of LIF and PMEF. Scale bar: 100 lm. (B) FACS sorting of SSEA-1+ cells from
dissociated and annexin-V immunolabeled EBs (previously treated with retinoic acid and a smoothened agonist) without and with pretreatment
with mitomycin C (1 lg/mL for 2 h) 12 h prior to sorting. The shift to the right indicates that the majority of SSEA-1+ cells expressed annexin-V
(but not GFP) after mitomycin C exposure. (C) Seven days following treatment with 1 lg/mL mitomycin C, dissociated EBs did not contain any
colonies of SSEA-1+ cells (right), but these pluripotent cells were present in untreated EBs (left). Scale bar 100 lm. (D) Dose–response of SSEA-1+
colonies 7 days in vitro after mitomycin C treatment. No colonies were found when EBs were treated with mitomycin C concentrations of 1 lg/
mL or above. *P < 0.05 compared to controls. (E) Toxicity of mitomycin C on ESCMNs showing statistically significant effects with concentrations
of 5 lg/mL or greater at all times points compared to controls. **P < 0.01 compared with controls of the same time point, by two-way ANOVA
and Bonferonni multiple comparisons.
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Figure 4. Reinnervation after delayed transplantation of embryonic stem cell-derived motoneurons (ESCMNs) treated with mitomycin C. (A, B)
Twitch force and (C, D) 50 Hz tetanic force of the medial gastrocnemius (MG) in delayed transplantation (1, 2, and 4 weeks delay). Traces in A
and C are from the same animals. No group showed a statistically significant difference compared to immediate transplants by Kruskal–Wallis
test. (A’) Four-week delayed transplant curve force with range (in gray) of response shown in (A) superimposed on EMG signal. Depolarization
triplets can be seen in the EMG. Arrow indicates the stimulus artifact. (E) Average MU force from transplanted mice obtained by force gradation
with increasing stimulus. (F) Motor unit number estimation. No statistical significant difference between groups. *Forces from immediate
transplants are those of HBGB6 ESCMNs not treated with mitomycin C. MU, motor unit.
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characteristics, such as contractile speed and fatigability,
were similar to normal MG muscles. The average MU
force was increased compared to normal MUs, but was
not statistically different between transplant groups
(Fig. 4E, Table 3). The motor unit number estimation
was ~13 (Fig. 4F), similar to the number we reported pre-
viously for immediate transplantation of untreated
ESCMNs.7 Together, these results demonstrate that incu-
bating ESCMNs with the antimitotic agent mitomycin C
not only prevented tumor formation, but also led to
engraftment and innervation following delays between
denervation and transplantation.
Discussion
In developing a clinically relevant model of cell transplan-
tation for denervation injury, we found that muscle
innervation decreased with increasing delays between
nerve transection and ESCMN transplantation. Concur-
rently with this, we found that about 50% of animals
developed teratocarcinomas, which arose from residual
pluripotent cells within the graft. We addressed tumorige-
nesis by pretreating the cultures with the antimitotic
agent mitomycin C, and found that this prevented cancer
formation and led to successful muscle innervation from
transplanted ESCMNs.
Motor force restoration
Following denervation, return of innervation can occur
within a finite time window (5 weeks in mice,24
12 weeks in rats,25 12–18 months in humans26), beyond
which functional recovery is poor.25,27,28 In the absence
of innervation, muscle contraction cannot be efficiently
restored.5
To this end, transplantation of MNs into either the
spinal cord gray matter or the peripheral nervous system
has been investigated and has demonstrated that trans-
planted MNs can reinnervate muscle fibers.29,30 Force
generation in our transplants performed either immedi-
ately7 or, as demonstrated here, after prolonged denerva-
tion recovered to about half of control forces, a finding
that is consistently demonstrated after immediate trans-
plantation by other groups as well.7–10,31–33 We estimated
that after transplantation, ~13–15 MUs innervated the
MG, whereas the mouse MG normally contains ~50
MUs.7,34 Given the sprouting capacity of MNs (up to five
times their native innervation ratio35), it would be
expected that all muscle fibers would be reinnervated, and
that close to normal force would be restored. There are
two possible explanations as to why this was not the case.
First, muscle fibers could have transformed from fast to
slow types and/or became smaller than normal. Second,
Table 2. Innervation of MG by transplanted mitomycin-treated
ESCMNs after prolonged denervation.
Transplantation
delay
Animals with MG
contraction (%)
Transplanted
animals
Immediate 0 (0%) 6
Immediate1 3 (50%) 6
1 week delay 6 (75%) 8
2 weeks delay 2 (33%) 6
4 weeks delay 2 (25%) 10
8 weeks delay ND ND
MG, medial gastrocnemius
1Immediate group representing HBGB6 ESCMNs transplanted without
mitomycin treatment. Mitomycin-treated ESCMNs transplanted imme-
diately after denervation (n = 6) did not generate contraction. Fisher’s
exact t-test P = 0.12.
Table 3. Physiological characteristics of ESCMN-transplanted MG compared to normal MG.
Animals
Contraction time
(msec)
Half-width
(msec)
Half-relaxation time
(msec) Sag index
Fatigue
index
Twitch–tetanic
ratio
Av. MU force
(mN)
Normal MG 44.10  1.65 39.71  1.74 15.31  1.45 0.99  0.03 0.02  0.01 0.40  0.03 1.63  0.20
Normal
soleus
64.40  10.19 113.52  17.37 69.38  11.60 1 ND 0.22  0.02 1.83  0.59
Transplanted animals
Immediate 47.25  7.83 108.32  37.241 76.07  29.811 0.97  0.04 0.17  0.08 0.50  0.14 3.32  1.25
1 week
delay
48.17  8.34 89.37  25.591 57.70  19.171 0.93  0.07 0.11  0.04 0.45  0.13 4.45  1.121
2 weeks
delay
44.22  5.20 79.51  9.64 49.42  4.57 0.89  0.07 0.08  0.01 0.61  0.041 5.19  2.161
4 weeks
delay
50.73  0.78 104.56  6.611 68.78  7.011 0.77  0.161 0.12  0.13 0.65  0.021 4.00  2.59
Data presented as mean  SD. Sag index and fatigue index as defined in Yohn et al.7 ND: not done; MG, medial gastrocnemius; MU, motor unit
1Statistically significant to normal MG (n = 5) by ANOVA and Tukey’s multiple comparisons (P < 0.05). No statistics performed on normal soleus
(n = 8).
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ESCMNs could have a more limited capacity to form
enlarged MUs compared to endogenous MNs. Support
for the former possibility comes from our previous
study,7 which showed an increase in the number of slow
muscle fibers in the mouse MG following ESCMN inner-
vation. Because slow fibers are smaller and less powerful
than fast fibers, this conversion would result in smaller
whole muscle force.36 However, aside from having half-
relaxation times similar to slow contracting muscles, all of
the contractile properties measured in the present study
including contraction time were typical of fast muscles
(Table 3). While we have no evidence that there is a cell-
autonomous reason for ESCMNs to have impaired capac-
ity to form enlarged MUs, the lack of activity resulting
from their reduced microcircuit environment may limit
their ability to form the number of axonal branches
required to expand their innervation ratio.37 Indeed,
while the average MU forces were higher than normal in
muscles innervated by ESCMNs, they were not five times
greater (Table 3). This inability of ESCMNs to form such
enlarged MUs would result in a large number of muscle
fibers remaining denervated, which, in turn, would lead
to a loss in force.
Timing of transplantation
We found that a delay of transplantation beyond 1 week
resulted in lower engraftment success, similar to previous
studies.32,38 At 1 week, the inflammatory environment
resulting from the transection has likely transformed to a
restorative milieu rich in neurotrophic factors, axonal
growth-promoting substrates, and supportive adhesion
molecules produced by activated Schwann cells.32,39 Given
that the rate of cellular death in the grafts is highest at
the time of transplantation,40 these survival signals may
be essential to sustain initial transplant survival. In fact,
during development, Schwann cells provide adhesion
molecules and trophic support for embryonic MN sur-
vival during the critical period of programmed cell
death.41 For these reasons, mitomycin C-treated ESCMNs
transplanted immediately likely failed to engraft; Schwann
cells had not yet proliferated to provide adhesive and
trophic support and glial cells normally present in EBs
would had been ablated by the mitomycin C treatment.
In fact, ESCMNs treated with mitomycin C always died
by the fifth day in vitro if not cocultured with glial cells,
a finding reported for embryonic neurons22 even in the
absence of mitomycin C treatment.
Tumor prevention
When considering translation of stem cell therapies, it is
crucial to be able to prevent cancer formation.16,42 Tumor
formation has been seen following the transplantation of
a number of cell types, including various human pluripo-
tent cell lines.43–47 The formation of teratocarcinomas is
dependent on the transplantation environment and the
host immune system,23 but requires the presence of resid-
ual pluripotent cells remaining postdifferentiation.43,48–51
Our previous publication used an allogeneic stem cell
line7 which may have triggered the host immune system
to reject residual pluripotent cells. Introduction of the
isogenic HBGB6 cell line could thus have contributed to
tumorigenesis. It has been shown that as few as two
undifferentiated stem cells in two million non-neoplastic
cells can form tumors in 60% of transplants; this rate
reached 100% of transplants when 20 undifferentiated
stem cells were transplanted.52 Given that current sorting
techniques are limited to the detection of 1 in 10,000,53
presorting of cells is currently inadequate. The use of mit-
omycin C – via a short 2-h exposure time prior to trans-
plantation – prevented early tumor formation by
eliminating tumorigenic cells.
Translational considerations
When considering cell-based therapies for MN loss, it is
pragmatic to first consider proximal peripheral nerve and
plexus injuries: these lead to significant deficits and are
associated with limited functional recovery.54 Commonly,
the approach to nerve injury is to delay invasive interven-
tions in order to identify spontaneous recovery.11 We
demonstrate that delayed transplantation of ESCMNs is
possible and effective if tumor formation is prevented.
Because the neurons in this model are transplanted into
the periphery, there is no connection with the central ner-
vous system, and thus no voluntary control. To obtain
control, this technique could be combined with functional
electrical stimulators to activate the transplanted neurons.
Alternatively, ESCMNs could perhaps be considered as
“placeholders,” preserving muscle fiber innervation until
endogenous axons return.
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